PRESS RELEASE published on 03/27/2025 at 07:30, 1 year 1 month ago Informations privilégiées / Information sur chiffre d’affaires annuel MaaT Pharma annonce une Augmentation de Capital de 13 millions d’euros avec ses actionnaires historiques et dévoile ses résultats annuels pour 2024. Des résultats positifs pour MaaT013 dans la maladie aiguë du greffon contre l'hôte (aGvH) et une soumission de l’AMM à l'EMA en Europe sont également annoncés Résultats Annuels Augmentation De Capital MaaT Pharma EMA MaaT013
BRIEF published on 01/21/2025 at 18:05, 1 year 4 months ago Résultats Positifs pour l'Essai Clinique de MaaT033 Biotechnologie Essai Clinique Sécurité Oncologie MaaT033
BRIEF published on 01/21/2025 at 18:05, 1 year 4 months ago Positive Results for MaaT033 Clinical Trial Biotechnology Security Oncology Clinical Trial MaaT033
PRESS RELEASE published on 01/21/2025 at 18:00, 1 year 4 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce un résultat positif du 2ème DSMB pour l'essai clinique de Phase 2b de MaaT033 pour patients recevant une allo-GCSH Essai Clinique Sécurité MaaT Pharma Tolérabilité Patients
PRESS RELEASE published on 12/10/2024 at 02:30, 1 year 5 months ago Inside Information / Other news releases
BRIEF published on 10/15/2024 at 07:35, 1 year 7 months ago Conclusion du recrutement pour l'essai clinique de MaaT Pharma Essai Clinique MaaT Pharma MaaT013 Avis DSMB Traitement AGvH
BRIEF published on 10/15/2024 at 07:35, 1 year 7 months ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 7 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte. Premiers résultats attendus en janvier 2025 MaaT Pharma MaaT013 Phase 3 ARES Maladie Aiguë Greffon Contre L'hôte
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 7 months ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
PRESS RELEASE published on 09/20/2024 at 09:07, 1 year 8 months ago Rapport Financier Semestriel 2024
Published on 05/23/2026 at 19:45, 8 hours 9 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 1 hour ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 1 hour ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 16:30, 11 hours 24 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 11 hours 57 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 5 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 5 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 8 hours ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 19:35, 1 day 8 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 9 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 9 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 15 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 15 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
